Page last updated: 2024-09-03

gefitinib and efatutazone

gefitinib has been researched along with efatutazone in 2 studies

Compound Research Comparison

Studies
(gefitinib)
Trials
(gefitinib)
Recent Studies (post-2010)
(gefitinib)
Studies
(efatutazone)
Trials
(efatutazone)
Recent Studies (post-2010) (efatutazone)
5,2315662,91925417

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cao, H; Ding, L; Dong, S; Du, Y; Fan, F; Feng, J; Li, H; Liu, S; Lou, R; Ma, R; Ni, J; Wang, Z; Wu, J; Zhao, X; Zhou, LL1
Cao, H; Ding, L; Feng, J; Li, H; Liu, S; Ma, R; Ni, J; Wang, Z; Wu, J; Zhang, XQ; Zhao, X; Zhou, LL1

Other Studies

2 other study(ies) available for gefitinib and efatutazone

ArticleYear
PPARĪ³ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARĪ³/PTEN/Akt pathway.
    Experimental cell research, 2017, 12-15, Volume: 361, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Survival Analysis; Thiazolidinediones

2017
Efatutazone and T0901317 exert synergistically therapeutic effects in acquired gefitinib-resistant lung adenocarcinoma cells.
    Cancer medicine, 2018, Volume: 7, Issue:5

    Topics: Adenocarcinoma of Lung; ATP Binding Cassette Transporter 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrocarbons, Fluorinated; Liver X Receptors; PPAR gamma; Sulfonamides; Thiazolidinediones

2018